10-Q · May 12, 2026
Revvity, Inc. achieved strong Q1 2026 results with revenue of $711.1 million and EPS of $1.06, both better than analyst expectations. The company highlighted growth in both its Diagnostics and Life Sciences segments,…
Earnings analysis · 10-Q
RVTY earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Revvity delivered Q2 revenue of $729.688 million and adjusted EPS of $1.41, up approximately 1.3% and 207% year over year, respectively, and both exceeded consensus estimates. Diagnostics growth and the raised full-year…
Read full summary
Revvity delivered Q2 revenue of $729.688 million and adjusted EPS of $1.41, up approximately 1.3% and 207% year over year, respectively, and both exceeded consensus estimates. Diagnostics growth and the raised full-year outlook of $2.83-$2.86 billion in revenue and $5.30-$5.40 adjusted EPS support a bullish trend, although Life Sciences declined organically and the China divestiture introduces execution risk. The filing extract does not include the income-statement detail needed to calculate current gross margin, operating margin, or free cash flow.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.41
- Segment
- Diagnostics: 11% organic growth, according to management's Q2 earnings commentary.
- Segment
- Life Sciences: organic revenue declined; the filing extract does not provide a segment revenue amount or decline percentage.
What stood out
-
Revenue grew year over year and sequentially
Q2 revenue was $729.688 million, up from $720 million in Q2 2025 and $711 million in Q1 2026, representing approximately 1.3% year-over-year and 2.6% sequential growth.
-
Adjusted EPS materially exceeded prior periods
Adjusted EPS was $1.41 versus $0.46 in Q2 2025 and $0.36 in Q1 2026, increases of approximately 207% year over year and 292% sequentially.
-
Q2 results beat consensus
Q2 adjusted EPS of $1.41 exceeded the $1.22 consensus estimate by $0.19, while revenue of $729.688 million exceeded the $703.597 million estimate by $26.091 million.
-
Diagnostics led segment performance
Diagnostics delivered 11% organic growth, providing the principal reported segment growth driver; Life Sciences organic revenue declined, indicating an uneven recovery across the portfolio.
-
Full-year outlook was raised
Management raised full-year pro forma revenue guidance to $2.83-$2.86 billion from $2.81-$2.84 billion and adjusted EPS guidance to $5.30-$5.40 from $5.20-$5.30.
-
Liquidity remained substantial
Cash and cash equivalents were $1,022.9 million at July 5, 2026. The debt portfolio was primarily fixed-rate, and no interest-rate derivative instruments were outstanding at quarter-end.
What to watch
-
China divestiture execution risk
The company agreed to divest its China Immunodiagnostics business, which represented approximately 6% of fiscal 2025 revenue and is expected to close by the end of 2027. Failure to execute the divestiture could result in unexpected transaction costs and operational disruption.
-
Large intangible asset impairment exposure
Net intangible assets totaled $8.8 billion at July 5, 2026. Adverse business changes or failure to grow the Life Sciences and Diagnostics segments could trigger impairment charges and pressure earnings.
-
Dividend may be reduced or eliminated
The company declared quarterly dividends of $0.07 per share for both Q2 and Q3 2026, but stated that the Board may reduce or eliminate the dividend to fund growth, repurchase shares, or conserve capital.
Management's outlook
Full-year 2026 pro forma guidance excludes the China Immunodiagnostics business. Revenue guidance was raised from $2.81-$2.84 billion to $2.83-$2.86 billion, and adjusted EPS guidance from $5.20-$5.30 to $5.30-$5.40. Pro forma organic revenue growth outlook is 4%-5%.
Earlier filings 4
10-K · February 24, 2026
Revvity frames its strategy around expanding Life Sciences and Diagnostics offerings through R&D, AI and targeted acquisitions while maintaining disciplined capital allocation. Using quarterly results published in the…
10-Q · May 6, 2025
Revvity reported Q1 revenue of $664,762 (in thousands), up $14,842 vs the year-ago quarter, with operating income rising to $72,230 (in thousands) from $44,116 and diluted EPS from continuing operations of $0.35 (vs…
10-Q · August 6, 2024
Revvity reported Q2 revenue of $691,685,000 (down $17,381,000 vs prior-year quarter) with continuing operating income of $85,724,000 (up $7,668,000 YoY) and net income of $55,360,000 (up $19,801,000 YoY). Cash and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.